Search by Drug Name or NDC
NDC 00527-5137-62 Oseltamivir Phosphate 30 mg/1 Details
Oseltamivir Phosphate 30 mg/1
Oseltamivir Phosphate is a ORAL SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Lannett Company, Inc.. The primary component is OSELTAMIVIR PHOSPHATE.
MedlinePlus Drug Summary
Oseltamivir is used to treat some types of influenza infection ('flu') in adults, children, and infants (older than 2 weeks of age) who have had symptoms of the flu for no longer than 2 days. This medication is also used to prevent some types of flu in adults and children (older than 1 year of age) when they have spent time with someone who has the flu or when there is a flu outbreak. Oseltamivir is in a class of medications called neuraminidase inhibitors. It works by stopping the spread of the flu virus in the body. Oseltamivir helps shorten the time that flu symptoms such as a stuffy or runny nose, sore throat, cough, muscle or joint aches, tiredness, headache, fever, and chills last. Oseltamivir will not prevent bacterial infections, which may occur as a complication of the flu.
Related Packages: 00527-5137-62Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Oseltamivir
Product Information
| NDC | 00527-5137 |
|---|---|
| Product ID | 0527-5137_0070049a-785f-56da-e063-6394a90adb25 |
| Associated GPIs | |
| GCN Sequence Number | 067561 |
| GCN Sequence Number Description | oseltamivir phosphate SUSP RECON 6 MG/ML ORAL |
| HIC3 | W5A |
| HIC3 Description | ANTIVIRALS, GENERAL |
| GCN | 29729 |
| HICL Sequence Number | 020607 |
| HICL Sequence Number Description | OSELTAMIVIR PHOSPHATE |
| Brand/Generic | Generic |
| Proprietary Name | Oseltamivir Phosphate |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | oseltamivir phosphate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | SUSPENSION |
| Route | ORAL |
| Active Ingredient Strength | 30 |
| Active Ingredient Units | mg/1 |
| Substance Name | OSELTAMIVIR PHOSPHATE |
| Labeler Name | Lannett Company, Inc. |
| Pharmaceutical Class | Neuraminidase Inhibitor [EPC], Neuraminidase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA213594 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00527-5137-62 (00527513762)
| NDC Package Code | 0527-5137-62 |
|---|---|
| Billing NDC | 00527513762 |
| Package | 1 BOTTLE, PLASTIC in 1 CARTON (0527-5137-62) / 1 SUSPENSION in 1 BOTTLE, PLASTIC |
| Marketing Start Date | 2023-07-13 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 0.24525 |
| Pricing Unit | ML |
| Effective Date | 2024-02-21 |
| NDC Description | OSELTAMIVIR 6 MG/ML SUSPENSION |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1, 5 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |